On July 31, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended six peptides for inclusion in the 503A Bulks List, despite prior FDA staff opposition. The peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—were chosen based on narrow votes, with one peptide, emideltide, being rejected. However, none of the peptides are FDA-approved, and legal compounding is not permitted without FDA acceptance. The panel’s findings revealed gaps in safety data, raising concerns about potential conflicts of interest due to a reconstituted committee with increased representation from peptide prescribers. Payers should prepare for continued cash-pay utilization and unregulated online purchases, emphasizing the need for medication monitoring and safety protocols.

News|Articles|July 31, 2026

FDA Panel Backs 6 Peptides for Compounding

Author(s) Pearl Steinzor

Fact checked by: Brooke McCormick

Listen

0:00 / 0:00

Key Takeaways

Six peptides received narrow advisory support for potential 503A Bulks List inclusion, an atypical outcome given FDA staff recommendations against all seven under review.
Legal compounding remains prohibited absent FDA acceptance and completion of proposed and final rulemaking; none of the substances is FDA-approved.
FDA reviewers cited short, underpowered studies insufficient for safety/efficacy across proposed indications, including limited BPC-157 trial data.
Committee reconstitution drew conflict-of-interest scrutiny, with increased representation from clinicians and businesses involved in prescribing, producing, or promoting peptides.
Payers should expect persistent cash-pay utilization and unregulated online procurement, necessitating rigorous medication reconciliation and adverse-event monitoring given sparse human safety data.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) closed its July 23-24 meeting with a string of narrow votes recommending 6 of the 7 peptides under review—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for the agency's 503A Bulks List, overriding career scientists who had recommended against including any of the 7.1,2 The panel's single rejection was emideltide (delta sleep-inducing peptide), voted down 7-6 with 1 abstention.1

On July 23, the committee voted 8-6, with 1 abstention, to recommend BPC-157, KPV, and TB-500; MOTS-c passed 7-5 with 2 abstentions.3 Semax and Epitalon were cleared on July 24 by similarly tight margins before emideltide became the meeting's only rejection.1 Observers in the room described an audible gasp when the first tally was announced, noting that a PCAC panel had rarely, if ever, voted against FDA staff's written recommendation. This follows FDA's decision to convene the reconstituted panel, whose July meeting materials disclosed that FDA scientists uniformly opposed adding any of the 7 substances.4

Panel's Recommendation Does Not Equal Legal Access

None of the peptides have been added to the 503A Bulks List, and none is an FDA-approved drug.1 The FDA must still decide whether to accept the committee's nonbinding recommendations and, if so, proceed through notice-and-comment rulemaking—a proposed rule, a public comment period, and a final rule—before compounding pharmacies could legally prepare the substances for patients. 4

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted that FDA still must formally adopt the advisers' recommendations before the peptides may be legally compounded.1 HHS Secretary Robert F. Kennedy Jr, who has called himself “a big fan” of peptides, could seek to expedite that process, though experts say it remains unclear what happens next or on what timeline.

Evidence Gaps and Panel Makeup Drew Scrutiny

FDA scientists' briefing materials found that available studies, including 5 trials of BPC-157, were short in duration, small in sample size, and insufficient to establish safety or effectiveness for the indications under review, which spanned ulcerative colitis, wound healing, obesity, osteoporosis, and opioid withdrawal.5

The reconstituted PCAC roster released ahead of the meeting drew scrutiny for including more health professionals who prescribe, produce, or promote peptides than prior iterations of the panel, a shift from committees historically composed mainly of academics and researchers. BPC-157 and TB-500 are both classified as doping substances by international sports authorities and remain widely sold online under "research use only" disclaimers despite the FDA's 2023 restrictions.

Managed Care Implications

For payers and health systems, the panel's votes mark an early procedural step rather than an imminent expansion of covered treatment options.1 Compounded drugs generally fall outside standard pharmacy benefit coverage, so patients would likely continue paying out of pocket even after any final rule takes effect.6

In the interim, managed care organizations should anticipate continued patient use of peptides sourced from unregulated online sellers and should prioritize medication reconciliation, safety counseling, and monitoring for adverse effects, particularly given the limited human safety data the FDA’s own reviewers cited during the review.1

References

Howard J. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. CNN. July 31, 2026. Accessed July 31, 2026. https://www.cnn.com/2026/07/31/health/what-are-peptides-fda-next-steps-wellness
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA. Accessed July 31, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
WATCH: FDA advisory panel narrowly backs use of several peptides favored by RFK Jr. Associated Press/PBS News. July 23, 2026. Accessed July 31, 2026. https://www.pbs.org/newshour/health/watch-live-fda-advisory-panel-considers-use-of-peptides
Steinzor P. FDA advisory panel weighs access to 7 popular peptides this week. AJMC®. July 23, 2026. Accessed July 31, 2026. https://www.ajmc.com/view/fda-advisory-panel-weighs-access-to-7-popular-peptides-this-week
Sun L, Nirappil F. FDA panel is reviewing if 7 peptides should be made more accessible, an RFK Jr priority. Washington Post. July 23, 2026. Accessed July 31, 2026. https://www.washingtonpost.com/health/2026/07/23/fda-advisory-panel-vote-recommending-7-peptides-broader-access/
Vega E. FDA advisory panel votes to loosen rules on BPC-157, TB-500, and MOTS-c despite agency scientists' opposition. Medical Daily. July 24, 2026. Accessed July 31, 2026. https://www.medicaldaily.com/fda-panel-votes-bpc-157-tb-500-mots-c-compounding-pharmacies-2026-476330

Trending on AJMC

1\ \ FDA Panel Backs 6 Peptides for Compounding 2\ \ Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89% 3\ \ FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies 4\ \ Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Read Original at The American Journal of Managed Care® (AJMC®) →

FDA Panel Backs 6 Peptides for Compounding | AJMC

FDA Panel Backs 6 Peptides for Compounding

Key Takeaways

Panel's Recommendation Does Not Equal Legal Access

Evidence Gaps and Panel Makeup Drew Scrutiny

Managed Care Implications

Related Content

Trending on AJMC